AVIR — Atea Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $324.03m
- $104.56m
U.S. STOCKS ON THE MOVE-Arcutis Biotherapeutics, Chegg, Li Auto
Atea Pharma climbs on FDA's fast-track tag for dengue treatment
Brief: Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted To AT-752 For Treatment Of Dengue
Brief: Atea Pharmaceuticals To Advance Global Phase 3 Registrational Study Of Bemnifosbuvir In High-Risk Non-Hospitalized Patients With Covid-19
U.S. RESEARCH ROUNDUP- Avalara, Global Blood Therapeutics, Tyson Foods
Atea Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results
Atea Pharma surges after promising COVID pill data
Atea Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Atea Pharmaceuticals Reports First Quarter 2022 Financial Results And Provides Business Update
Atea Pharmaceuticals Inc expected to post a loss of 58 cents a share - Earnings Preview
Brief: Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (At-527) Toxicology Data
U.S. RESEARCH ROUNDUP- Autozone, Domino's Pizza, Salesforce.com
U.S. RESEARCH ROUNDUP-Alx Oncology Holdings, First Horizon, Intricon
Atea Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Atea Pharmaceuticals Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Business Update
Atea Pharmaceuticals Inc expected to post earnings of 17 cents a share - Earnings Preview
Brief: Atea Pharmaceuticals Reports Data On Bemnifosbuvir
Brief: Atea Pharmaceuticals Highlights Strategic Priorities For 2022